Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting CHARLESTOWN, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation investigational gene therapy intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 26th Annual Scientific Meeting of Neuromuscular Study Group (NMSG), September 26-28, 2025, in Stresa, Ita...
A director at Safestore Holdings bought 4,656 shares at 644p and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 - Non-exclusive license for Solid’s proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio’s gene therapy for dysferlin-related limb-girdle muscular dystrophy - - Solid to receive an upfront payment and is eligible for certain development and sales milestones and tiered royalties on net sales -- Solid continues to expand collaborative efforts for AAV-SLB101 with more than 25 agreements and licenses executed to date - CHARLESTOWN, Mass...
Last week’s EPRA conference provided cautious optimism on listed European real estate. The segment offers a mix of risks and opportunities, with discounted valuations presenting attractive entry points. We downgrade Care Property Invest (Underperform vs Neutral, TP €12 vs €13.5); we lower our TPs for British Land, Landsec, Shurgard, and Xior Student Housing; we raise our TPs for URW, Wereldhave and VGP. In conclusion we favour logistics, retail, Spain, and CEE for growth, and Switzerland remains...
Frequency Electronics, Inc. Announces First Quarter Fiscal Year 2026 Financial Results • Announces $20 million share repurchase authorization MITCHEL FIELD, N.Y., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) is pleased to announce its financial results for the first quarter of fiscal year 2026. Revenue for the first quarter ended July 31, 2025, was approximately $13.8 million, a decrease from the $15.1 million reported for the same period of fiscal year 2025. Operating income for the first quarter of fiscal...
Frequency Electronics Announces First Quarter Fiscal 2026 Financial Results Conference Call: Thursday, September 11, 2025, at 4:30 PM ET MITCHEL FIELD, N.Y., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (NASDAQ: FEIM), will hold a conference call to discuss results for the first quarter of its fiscal year 2026, ended April 30, 2026, on Thursday, September 11, 2025, at 4:30 PM Eastern Time. This call is being webcast by Issuer Direct Corporation and can be accessed in the Investor Relations section of Frequency’s web site at . Investors and analysts may also access the c...
Solid Biosciences to Participate at Upcoming Investor Conferences CHARLESTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2025 Citi Biopharma Back to School ConferenceBo Cumbo, President and CEO, will participate in a fireside chat on Tuesday, September 2, 2025, at 1:45 p.m. ET. A live webcast will be available by . Cantor Global Healthcare ConferenceMr. ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.